SMARCA1

Across TCGA pan-cancer cohorts, SMARCA1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMARCA1 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher SMARCA1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMARCA1 expression acts as an unfavorable survival marker.

KIRP, BLCA, and LIHC are the cancer types where SMARCA1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.132	0.863	<.001	30	view →
BLCA	OS	Median	All	0.190	0.703	<.001	18	view →
LIHC	DFS	Median	All	0.077	0.527	.002	15	view →
LGG	OS	Median	All	0.214	0.889	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMARCA1–KIRP (DFS)

Open the KIRP breakdown →